This method was performed by seeding a single B-cell in each well of a 96-well plate in the presence or absence of EGF (100 ng/ml) or NHL-a101 or NHL-a102 (10 ng/ml) and the selective EGFR inhibitor AG1478 (250 nM) or the ErbB2 inhibitor AG879 (2 μM). The gene discussed is EGF; the disease is non-Hodgkin lymphoma.